The federal agency authorized the use of the Eli Lilly & Co. weight loss drug for “treatment of moderate to severe ...

Zepbound is the first prescription drug approved specifically to treat the common condition. The Food and Drug Administration ...

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has been approved by the Food and Drug Administration for ...

Zepbound, Eli Lilly’s weight loss drug, can now be used to treat obstructive sleep apnea in adults with obesity, the FDA said ...

The FDA said studies have shown that by aiding weight loss, Zepbound improves sleep apnea symptoms in some patients.

The U.S. Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the ...

In addition to things like sleep apnea, the weight-loss drugs could lead to more joint replacements, said Sara Stahl, director of healthcare research at market analysis firm AlphaSense.

In addition to treatment of things like sleep apnea, the weight-loss drugs could lead to more joint replacements, said Sara Mallatt, director of healthcare research at market analysis firm AlphaSense.

Tirzepatide is approved for moderate-to-severe obstructive sleep apnea (OSA) in adults with ... reductions in breathing disruptions and weight loss with tirzepatide. Nearly half of trial ...

(Reuters) - The U.S. Food and Drug Administration on Friday approved Eli Lilly (NYSE:LLY)'s weight-loss treatment, Zepbound, for obstructive sleep apnea ... to a class of drugs called GLP-1 ...

Approval for use beyond weight-loss could be a shot in the arm for the companies at a time when demand for the drugs is already surging. Obstructive sleep apnea affects roughly 1 billion people ...